A new look at dry eye disease and its treatment
- 1 March 2000
- journal article
- review article
- Published by Springer Nature in Advances in Therapy
- Vol. 17 (2) , 84-93
- https://doi.org/10.1007/bf02854841
Abstract
This review examines the impact of moderate to severe dry eye disease on daily life and medical-resource utilization. The results suggest that current treatment paradigms can lead to unacceptable costs in both quality of life and progressive use of healthcare resources. Evidence linking this disease to T-cell-mediated inflammatory processes lays the foundation for understanding the clinical benefits of topical cyclosporine, an immunomodulatory and anti-inflammatory agent.Keywords
This publication has 24 references indexed in Scilit:
- Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease11Reprint requests to: Linda Lewis, 575 Anton Blvd, Suite 900, Costa Mesa, CA 92626.Ophthalmology, 2000
- Patient Self-Reports in Pharmacoeconomic StudiesPharmacoEconomics, 1999
- A comparative approach to topical cyclosporine therapyEye, 1997
- Topical cyclosporin treatment of keratoconjunctivitis sicca in secondary Sjögren's syndromeActa Ophthalmologica, 1994
- Topical Cyclosporin A in the Treatment of Anterior Segment Inflammatory DiseaseCornea, 1993
- Cytokines and autoimmune diseaseClinical Immunology and Immunopathology, 1991
- Background, Immunology, and PharmacologyCornea, 1990
- Senile atrophy of the human lacrimal gland: the contribution of chronic inflammatory disease.British Journal of Ophthalmology, 1984
- Diagnostic implications of tear protein profiles.British Journal of Ophthalmology, 1984
- The Use of Cyclosporin A in clinical Organ GraftingAnnals of Surgery, 1982